Cancer Genetics Inc (NASDAQ:CGIX) has received a consensus recommendation of “Hold” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $6.00.

A number of equities analysts have commented on CGIX shares. HC Wainwright set a $6.00 price objective on shares of Cancer Genetics and gave the stock a “buy” rating in a report on Wednesday, November 29th. Zacks Investment Research upgraded shares of Cancer Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th. ValuEngine downgraded shares of Cancer Genetics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Maxim Group started coverage on shares of Cancer Genetics in a research report on Thursday, December 7th. They issued a “buy” rating and a $6.00 target price for the company.

How to Become a New Pot Stock Millionaire

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp grew its position in shares of Cancer Genetics by 61.0% during the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after buying an additional 12,168 shares during the last quarter. Granahan Investment Management Inc. MA grew its position in shares of Cancer Genetics by 26.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after buying an additional 49,371 shares during the last quarter. Two Sigma Securities LLC grew its position in shares of Cancer Genetics by 363.0% during the 4th quarter. Two Sigma Securities LLC now owns 67,677 shares of the medical research company’s stock valued at $125,000 after buying an additional 53,061 shares during the last quarter. Perkins Capital Management Inc. grew its position in shares of Cancer Genetics by 22.7% during the 4th quarter. Perkins Capital Management Inc. now owns 989,700 shares of the medical research company’s stock valued at $1,831,000 after buying an additional 183,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Cancer Genetics by 61.9% during the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after buying an additional 197,619 shares during the last quarter. 17.96% of the stock is owned by institutional investors.

Shares of Cancer Genetics (NASDAQ CGIX) remained flat at $$1.90 during mid-day trading on Friday. The company’s stock had a trading volume of 41,217 shares, compared to its average volume of 130,656. Cancer Genetics has a 52-week low of $1.55 and a 52-week high of $5.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.01 and a current ratio of 2.01. The stock has a market cap of $51.25, a price-to-earnings ratio of -1.96 and a beta of 1.24.

ILLEGAL ACTIVITY WARNING: “Cancer Genetics Inc (CGIX) Receives Consensus Recommendation of “Hold” from Brokerages” was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/cancer-genetics-inc-cgix-receives-consensus-recommendation-of-hold-from-brokerages/1957699.html.

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.